Indeed, targeting cDC2s via an antigen coupled to an anti-DC-SIGN antibody or glycans (LeB), in a B16-OVA mouse model with DCs expressing the human DC-SIGN, induces the priming of antigen-specific cytotoxic T-cells, and tumor regression is observed if the treatment is combined with Treg depletion [150]. The gene discussed is CD209; the disease is neoplasm.